239 related articles for article (PubMed ID: 26489881)
1. Pretreatment with rivaroxaban attenuates stroke severity in rats by a dual antithrombotic and anti-inflammatory mechanism.
Dittmeier M; Kraft P; Schuhmann MK; Fluri F; Kleinschnitz C
Thromb Haemost; 2016 Apr; 115(4):835-43. PubMed ID: 26489881
[TBL] [Abstract][Full Text] [Related]
2. Dabigatran Etexilate Reduces Thrombin-Induced Inflammation and Thrombus Formation in Experimental Ischemic Stroke.
Dittmeier M; Wassmuth K; Schuhmann MK; Kraft P; Kleinschnitz C; Fluri F
Curr Neurovasc Res; 2016; 13(3):199-206. PubMed ID: 27184031
[TBL] [Abstract][Full Text] [Related]
3. In Models of Intracerebral Hemorrhage, Rivaroxaban is Superior to Warfarin to Limit Blood Brain Barrier Disruption and Hematoma Expansion.
Sawada S; Ono Y; Egashira Y; Takagi T; Tsuruma K; Shimazawa M; Iwama T; Hara H
Curr Neurovasc Res; 2017; 14(2):96-103. PubMed ID: 27993122
[TBL] [Abstract][Full Text] [Related]
4. Rivaroxaban and apixaban reduce hemorrhagic transformation after thrombolysis by protection of neurovascular unit in rat.
Kono S; Yamashita T; Deguchi K; Omote Y; Yunoki T; Sato K; Kurata T; Hishikawa N; Abe K
Stroke; 2014 Aug; 45(8):2404-10. PubMed ID: 24984746
[TBL] [Abstract][Full Text] [Related]
5. Effect of rivaroxaban on prothrombin fragment 1+2 compared with warfarin in patients with acute cardioembolic stroke: Insight from its serial measurement.
Hagii J; Tomita H; Metoki N; Tamai Y; Saito S; Shiroto H; Hitomi H; Kamada T; Seino S; Takahashi K; Sasaki S; Yasujima M; Okumura K
Thromb Res; 2016 Dec; 148():9-14. PubMed ID: 27764730
[TBL] [Abstract][Full Text] [Related]
6. Reduction of intracerebral hemorrhage by rivaroxaban after tPA thrombolysis is associated with downregulation of PAR-1 and PAR-2.
Morihara R; Yamashita T; Kono S; Shang J; Nakano Y; Sato K; Hishikawa N; Ohta Y; Heitmeier S; Perzborn E; Abe K
J Neurosci Res; 2017 Sep; 95(9):1818-1828. PubMed ID: 28035779
[TBL] [Abstract][Full Text] [Related]
7. Insights into the role of thrombin in the pathogenesis of recurrent ischaemia after acute coronary syndrome.
Weitz JI
Thromb Haemost; 2014 Nov; 112(5):924-31. PubMed ID: 25030773
[TBL] [Abstract][Full Text] [Related]
8. Rivaroxaban does not increase hemorrhage after thrombolysis in experimental ischemic stroke.
Ploen R; Sun L; Zhou W; Heitmeier S; Zorn M; Jenetzky E; Veltkamp R
J Cereb Blood Flow Metab; 2014 Mar; 34(3):495-501. PubMed ID: 24346690
[TBL] [Abstract][Full Text] [Related]
9. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
Cheng JW; Barillari G
J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
[TBL] [Abstract][Full Text] [Related]
10. Direct oral anticoagulants are associated with limited damage of endothelial cells of the blood-brain barrier mediated by the thrombin/PAR-1 pathway.
Puech C; Delavenne X; He Z; Forest V; Mismetti P; Perek N
Brain Res; 2019 Sep; 1719():57-63. PubMed ID: 31121158
[TBL] [Abstract][Full Text] [Related]
11. Thrombin generation and other coagulation parameters in a patient with homozygous congenital protein S deficiency on treatment with rivaroxaban.
Tripodi A; Martinelli I; Chantarangkul V; Clerici M; Artoni A; Passamonti S; Peyvandi F
Int J Hematol; 2016 Feb; 103(2):165-72. PubMed ID: 26586461
[TBL] [Abstract][Full Text] [Related]
12. Arterial antithrombotic activity of rivaroxaban, an orally active factor Xa inhibitor, in a rat electrolytic carotid artery injury model of thrombosis.
Parry TJ; Huang Z; Chen C; Connelly MA; Perzborn E; Andrade-Gordon P; Damiano BP
Blood Coagul Fibrinolysis; 2011 Dec; 22(8):720-6. PubMed ID: 21986468
[TBL] [Abstract][Full Text] [Related]
13. Early initiation of a factor Xa inhibitor can attenuate tissue repair and neurorestoration after middle cerebral artery occlusion.
Komori M; Ago T; Wakisaka Y; Nakamura K; Tachibana M; Yoshikawa Y; Shibahara T; Yamanaka K; Kuroda J; Kitazono T
Brain Res; 2019 Sep; 1718():201-211. PubMed ID: 31103522
[TBL] [Abstract][Full Text] [Related]
14. Use of rivaroxaban in patients with stroke.
Toni D; Carolei A; Caso V; Consoli D; Del Sette M; Inzitari D; Melis M; Micieli G; Provinciali L; Ricci S; Santalucia P; Toso V
Neurol Sci; 2017 May; 38(5):745-754. PubMed ID: 28238163
[TBL] [Abstract][Full Text] [Related]
15. Rivaroxaban in the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation: Clinical Implications of the ROCKET AF Trial and Its Subanalyses.
Spencer RJ; Amerena JV
Am J Cardiovasc Drugs; 2015 Dec; 15(6):395-401. PubMed ID: 26062914
[TBL] [Abstract][Full Text] [Related]
16. Anticoagulation with dabigatran does not increase secondary intracerebral haemorrhage after thrombolysis in experimental cerebral ischaemia.
Sun L; Zhou W; Ploen R; Zorn M; Veltkamp R
Thromb Haemost; 2013 Jul; 110(1):153-61. PubMed ID: 23615682
[TBL] [Abstract][Full Text] [Related]
17. Point-of-Care Testing of Coagulation in Patients Treated With Non-Vitamin K Antagonist Oral Anticoagulants.
Ebner M; Peter A; Spencer C; Härtig F; Birschmann I; Kuhn J; Wolf M; Winter N; Russo F; Zuern CS; Blumenstock G; Ziemann U; Poli S
Stroke; 2015 Oct; 46(10):2741-7. PubMed ID: 26272385
[TBL] [Abstract][Full Text] [Related]
18. Treatment with Edoxaban Attenuates Acute Stroke Severity in Mice by Reducing Blood-Brain Barrier Damage and Inflammation.
Bieber M; Foerster KI; Haefeli WE; Pham M; Schuhmann MK; Kraft P
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576055
[TBL] [Abstract][Full Text] [Related]
19. Measuring Rivaroxaban in a clinical laboratory setting, using common coagulation assays, Xa inhibition and thrombin generation.
Molenaar PJ; Dinkelaar J; Leyte A
Clin Chem Lab Med; 2012 Oct; 50(10):1799-807. PubMed ID: 23089710
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the effect of edoxaban, a direct factor Xa inhibitor, with a direct thrombin inhibitor, melagatran, and heparin on intracerebral hemorrhage induced by collagenase in rats.
Shirasaki Y; Morishima Y; Shibano T
Thromb Res; 2014 Apr; 133(4):622-8. PubMed ID: 23932349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
